Long-term data released in January 2026 definitively confirms that the AREDS2 formula effectively slows the progression of age-related macular degeneration (AMD) while eliminating cancer risks associated with older formulations.
The National Eye Institute (NEI) has concluded its 10-year follow-up study on the AREDS2 clinical trial. The results settle a decade-long debate regarding the optimal composition of eye supplements for patients with intermediate to advanced AMD.
The Critical Switch: Lutein over Beta-Carotene
The original AREDS formula contained beta-carotene, which was later found to double the risk of lung cancer in smokers and former smokers. The AREDS2 study replaced beta-carotene with 10 mg of Lutein and 2 mg of Zeaxanthin. The 10-year data confirms:
- Safety: The replacement formula has zero association with increased lung cancer risk, making it safe for all patient demographics.
- Efficacy: The lutein/zeaxanthin combination is approximately 20% more effective at preventing progression to late AMD compared to the original beta-carotene formula.
Sustained Protection
The study showed that adherence to the AREDS2 formula reduced the overall risk of developing advanced AMD by 25-30% over the 10-year period. This reduction was consistent across patients with intermediate dry AMD, significantly preserving central vision and quality of life.
"The era of beta-carotene in eye supplements is officially over. The AREDS2 formula is the only evidence-based standard for AMD care."
FuturePharma's Standard
In light of these findings, FuturePharma is conducting a full audit of our ophthalmology portfolio. We are committed to distributing only AREDS2-aligned supplements (containing Lutein, Zeaxanthin, Zinc, Copper, Vitamin C, and E) to ensure our partners in Albania and Kosovo are providing the safest care possible.